PSMD10 Antibody

說明書

中文名稱：

PSMD10兔多克隆抗體
貨號：

CSB-PA018899GA01HU
規格：

￥3,900
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O75832
基因名：

PSMD10
別名：

26S proteasome non-ATPase regulatory subunit 10 antibody; 26S proteasome regulatory subunit p28 antibody; Ankyrin repeat protein antibody; dJ889N15.2 antibody; Gankyrin antibody; Hepatocellular carcinoma-associated protein p28 II antibody; p28 antibody; p28(GANK) antibody; Proteasome (prosome, macropain) 26S subunit, non ATPase, 10 antibody; Proteasome 26S S10 antibody; PSD10_HUMAN antibody; Psmd10 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Human PSMD10
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產品提供形式：

Liquid
應用范圍：

ELISA,WB
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pathway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis.; Acts as an proto-oncoprotein by being involved in negative regulation of tumor suppressors RB1 and p53/TP53. Overexpression is leading to phosphorylation of RB1 and proteasomal degradation of RB1. Regulates CDK4-mediated phosphorylation of RB1 by competing with CDKN2A for binding with CDK4. Facilitates binding of MDM2 to p53/TP53 and the mono- and polyubiquitination of p53/TP53 by MDM2 suggesting a function in targeting the TP53:MDM2 complex to the 26S proteasome. Involved in p53-independent apoptosis. Involved in regulation of NF-kappa-B by retaining it in the cytoplasm. Binds to the NF-kappa-B component RELA and accelerates its XPO1/CRM1-mediated nuclear export.
基因功能參考文獻：
1. gankyrin alleviates oxidative stress via mTORC1 pathway activation. PMID: 30420909
2. the pro-malignant effects of Gankyrin in CRC cells PMID: 29883699
3. Low Gankyrin expression is associated with drug resistance in Breast Cancer. PMID: 29286612
4. the results demonstrated that the lentivirus-mediated shRNA vector-based RNAi expression system is an efficient method to silence PSMD10 gene expression in the MM RPMI-8226 cell line. It may provide a basis to study the role of PSMD10 in tumor cells, and may be a reliable gene therapy strategy in the clinic PMID: 28677774
5. Gankyrin sustains PI3K/GSK-3beta/beta-catenin signal activation and promotes an aggressive colorectal cancer phenotype and disease progression. PMID: 27835604
6. PSMD10/gankyrin has a role in inducing autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression PMID: 25905985
7. we conclude that FXR-Gank-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR-Gank-based therapy for treatment of patients with hepatoblastoma PMID: 28535186
8. p28 assists the proteolytic core particle to select a specific conformation of the ATPase ring for regulatory particle engagement and is released in a shoehorn-like fashion in the last step of the chaperone-mediated proteasome assembly. PMID: 28689658
9. gankyrin regulates HIF-1alpha protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation PMID: 26364616
10. The positive feedback regulation involving gankyrin and Nrf2 modulates a series of antioxidant enzymes, thereby lowering intracellular ROS and conferring a steadier intracellular environment, which prevents mitochondrial damage and cell death induced by excessive oxidative stress. PMID: 27091842
11. Gankyrin enhanced gastric cancer cell proliferation by regulating cell cycle-related proteins and by activating PI3K/AKT signaling pathway. Gankyrin played an important role in gastric carcinogenesis and could be a potential effective therapeutic target for enhancing chemosensitivity to 5-fluorouracil and cisplatin. PMID: 28653901
12. gankyrin is an oncoprotein that can be modified by small molecules in tumor cell lines PMID: 27046077
13. Gankyrin overexpression activates mTORC1 signaling and accelerating TSC2 degradation in colorectal tumor cells. PMID: 26975632
14. Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53. Gankyrin is involved in the regulation of cell signaling pathways, with particular reference to RhoA/ROCK/PTEN/PI3K/Akt, beta-catenin, IL-6/STAT3, and IL-1beta/IRAK-1 inflammatory signaling. Review. PMID: 26819208
15. Gankyrin-overexpressed non-small cell lung cancer patients had a significantly shorter survival time PMID: 26554593
16. Results identified rs111638916 SNP in the PSMD10 3'-UTR as a risk factor for gastric cancer (GC) and acted as a tumor promoting factor. SNP rs111638916 was also regulated by miR-505, resulting in its up-regulation in patients with GA and AA genotypes. PMID: 26394032
17. p28GANK expression was increased in metastatic ESCC tissues and cells, and p28GANK knockdown decreased the metastatic ability of ESCC cells. PMID: 25634618
18. This study identifies gankyrin, for the first time, as new potential predictive and oncogenic factor of well-differentiated/dedifferentiated liposarcoma, suggesting the potential for service as a future Liposarcoma therapeutic approach. PMID: 25238053
19. On the base results of present study one can suggests the p28GANK being useful as a predictive marker for patient prognosis and a novel therapeutic target for gastric cancer. PMID: 25842830
20. IL-1beta stimulation causes sequential phosphorylation of IRAK-1, c-Jun N-terminal kinase, and p300 and enhances recruitment of the p300/CBP/NF-Y complex to Gankyrin promoter PMID: 25294684
21. Gankyrin is aberrantly expressed beginning at the initiation stage and plays an important role in the initiation, promotion, and progression of hepatocarcinogenesis. PMID: 24999092
22. Gankyrin may be functional in cervical carcinogenesis and metastasis. PMID: 24751719
23. MiR-605 directly targets and represses PSMD10 expression. PMID: 25131931
24. The intensity of gankyrin expression was 'positive' in two cases (20%) and 'strongly positive' in eight cases (80%). PMID: 24460153
25. Gankyrin deletion abrogated the increased metastatic potential of breast cancer cells under hypoxic conditions partly through regulating Ecadherin. PMID: 24337075
26. Gankyrin is crucial for cholangiocarcinoma carcinogenesis and metastasis by activating IL-6/STAT3 signaling pathway through down-regulating Rb protein. PMID: 24037855
27. Activation of the interleukin (IL)-8 signaling pathway by Gankyrin. PMID: 23576566
28. Data indicate that miR-214 down-regulated the expression of PSMD10 (gankyrin) and ASF1B, and gankyrin inhibition induced an increase of P53 mRNA levels. PMID: 23100276
29. In colorectal cancer development, gankyrin would control stem cell behavior by regulating the expression of stemness factors. PMID: 23508981
30. findings suggest that Gankyrin is crucial for breast cancer metastasis PMID: 22890318
31. gankyrin was identified in normal breasts and overexpressed in invasive breast cancers. The overexpression of gankyrin was associated with extensive intraductal carcinoma and ErbB2 expression in breast cancer. PMID: 23276718
32. Increased expression of p28GANK is correlated with glioma. PMID: 22913315
33. the roles and underlying mechanisms by which gankyrin is involved in tumorigenesis and cancer metastasis PMID: 22913272
34. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53. PMID: 22230478
35. Upregulation of p28(GANK) expression subsequently enhanced the transcription activity of beta-catenin. PMID: 21691299
36. Gankyrin overexpression is a prevalent event in human oral cancer and occurs during the early stages of oral carcinogenesis, thus being a viable therapeutic or chemopreventive target in oral cancer PMID: 21868508
37. we detected a significant correlation between p28(GANK) expression and p-AKT levels in a cohort of hepatocellular carcinoma biopsies, and the combination of these two parameters is a more powerful predictor of poor prognosis. PMID: 21254169
38. these findings suggest that down-regulation of P28GANK gene expression could sensitize osteosarcoma cells to chemotherapeutic drugs by down-regulation of the MDR-1 and Bcl-2 and up-regulation of Bax gene expression. PMID: 21287809
39. Gankyrin could enhance pancreatic cancer cell proliferation by promoting cell cycle progression and p53 degradation. PMID: 20483533
40. analysis of how gankyrin unfolds under force via multiple distinct pathways PMID: 20371329
41. Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis. PMID: 20628200
42. Gankyrin was overexpressed in colorectal cancer tissues and cell lines compared to controls, and gankyrin expression was correlated with TNM stages and metastasis of CRC. PMID: 19901563
43. p28(GANK) has potential implications for hepatocellular carcinoma progression under the endoplasmic reticulum stress conditions PMID: 19736567
44. Overexpression of p28/gankyrin in HCC plays an important role and contributes to the metastasis potential in the process of carcinogenesis. PMID: 12174370
45. MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. PMID: 12525503
46. gankyrin interactions with partner proteins are mediated by residues situated on its concave surface PMID: 14573599
47. X-ray structure of gankyrin. PMID: 14997555
48. The hepatocytic staining for p28(GANK) is clearly useful in differentiating hepatocyte-originated carcinoma from non-HCC. p28(GANK) may be used as an ancillary marker for the diagnosis of HCC. PMID: 15221469
49. Structural comparison with p16(INK4A) identified several residues of gankyrin that are potentially important for CDK4 binding PMID: 15379554
50. role of p28GANK as a highly expressed oncoprotein in hepatocellular carcinoma by in situ examination PMID: 15910504
顯示更多

收起更多
亞細胞定位：

Cytoplasm. Nucleus.
組織特異性：

Tends to be up-regulated in cancer cells with RAS mutations, including lung cancers and adenocarconimas (at protein level).
數據庫鏈接：

HGNC: 9555

OMIM: 300880

KEGG: hsa:5716

STRING: 9606.ENSP00000217958

UniGene: Hs.522752

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human